ALA Stock Overview
A biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Arovella Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.18 |
| 52 Week High | AU$0.21 |
| 52 Week Low | AU$0.081 |
| Beta | -0.023 |
| 11 Month Change | -5.26% |
| 3 Month Change | 24.14% |
| 1 Year Change | 122.22% |
| 33 Year Change | 350.00% |
| 5 Year Change | 181.25% |
| Change since IPO | -95.89% |
Recent News & Updates
Shareholder Returns
| ALA | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -12.2% | -11.8% | 1.5% |
| 1Y | 122.2% | 39.8% | 17.2% |
Return vs Industry: ALA exceeded the Australian Pharmaceuticals industry which returned 39.8% over the past year.
Return vs Market: ALA exceeded the Australian Market which returned 17.2% over the past year.
Price Volatility
| ALA volatility | |
|---|---|
| ALA Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: ALA has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: ALA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Michael Baker | www.arovella.com |
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021.
Arovella Therapeutics Limited Fundamentals Summary
| ALA fundamental statistics | |
|---|---|
| Market cap | AU$194.92m |
| Earnings (TTM) | -AU$8.75m |
| Revenue (TTM) | AU$1.95m |
97.2x
P/S Ratio-21.7x
P/E RatioIs ALA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALA income statement (TTM) | |
|---|---|
| Revenue | AU$1.95m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.95m |
| Other Expenses | AU$10.70m |
| Earnings | -AU$8.75m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0083 |
| Gross Margin | 100.00% |
| Net Profit Margin | -448.03% |
| Debt/Equity Ratio | 0% |
How did ALA perform over the long term?
See historical performance and comparison